BAY 94‐9027 (damoctocog alfa pegol; Jivi®; Bayer AG, Germany) is an extended half‐life B‐domain–deleted,...
Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for...
Prophylactic treatment regimens lead to improvements in health-related quality- of-life (HRQoL) among individuals with...
The current interest in recombinant factor VIII (rFVIII) products stems from the fact that...
Adeno-associated virus (AAV)-mediated gene therapy is a promising treatment option for patients with hemophilia...
Discrepancies among several assays results can be observed within the laboratory monitoring of FVIII...
A recently published review has focused on the evolution of treatment landscape of hemophilia...
The longest life expectancy makes hemophiliacs susceptible to diseases not related to haemophilia and...
Gene therapy has the potential to revolutionise treatment for patients with haemophilia and is...
In recent years there have been important developments regarding the availability of highly innovative...